SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID Drug Patent Profile

When do Sodium Picosulfate, Magnesium Oxide And Anhydrous Citric Acid patents expire, and what generic alternatives are available?

Sodium Picosulfate, Magnesium Oxide And Anhydrous Citric Acid is a drug marketed by Hetero Labs Ltd V and is included in one NDA.

The generic ingredient in SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

Summary for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID at DailyMed

Recent Clinical Trials for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Universitari Vall d'Hebron Research Institute	Phase 4
The Cleveland Clinic	Phase 4
Ferring Pharmaceuticals	Phase 4

See all SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID clinical trials

US Patents and Regulatory Information for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID	citric acid; magnesium oxide; sodium picosulfate	FOR SOLUTION;ORAL	212789-001	Jul 18, 2022		RX	No	Yes

Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid: Market Dynamics, Patent Exposure and Financial Trajectory

Last updated: August 7, 2026

Sodium picosulfate, magnesium oxide and anhydrous citric acid is a prescription bowel-preparation combination used before colonoscopy. In the United States, the molecule is associated with Prepopik and the ready-to-drink product Clenpiq. The market is mature, price-sensitive and clinically differentiated by low preparation volume rather than by novel pharmacology.

The commercial outlook depends on three factors: continued colonoscopy volumes, payer willingness to reimburse low-volume preparations, and generic substitution. Branded revenue has faced pressure from competing products, institutional purchasing and generic or authorized-generic alternatives. The product has no biosimilar exposure because it is a small-molecule gastrointestinal preparation.

What is sodium picosulfate, magnesium oxide and anhydrous citric acid?

The combination is an oral bowel-cleansing agent. Sodium picosulfate stimulates colonic motility after conversion to its active metabolite. Magnesium oxide and anhydrous citric acid react in solution to generate magnesium citrate, which produces an osmotic laxative effect.

The U.S. products are:

Product	Dosage form	U.S. sponsor or commercial owner	FDA milestone	Primary commercial position
Prepopik	Powder for oral solution	Ferring Pharmaceuticals originally; U.S. rights later associated with Bausch Health	Approved 2012	Low-volume split-dose bowel preparation
Clenpiq	Ready-to-drink oral solution	Ferring Pharmaceuticals originally; U.S. commercial rights associated with Bausch Health	Approved 2017	Convenience-oriented liquid formulation
Generic equivalents	Oral solution or powder for solution	Multiple ANDA applicants or generic manufacturers	Subject to FDA ANDA approvals	Price competition and substitution

Prepopik contains two packets taken with clear liquids. Clenpiq is supplied as a ready-to-drink solution, reducing preparation steps for patients and pharmacies. Both products require substantial additional clear-liquid intake and carry warnings concerning fluid and electrolyte abnormalities.[1][2]

How large is the sodium picosulfate bowel-prep market?

The product competes in the U.S. prescription colonoscopy-preparation market rather than in a standalone active-ingredient market. Public companies generally do not disclose revenue for sodium picosulfate, magnesium oxide and anhydrous citric acid separately.

Demand is tied to colonoscopy procedure volumes. In the U.S., colorectal cancer screening guidelines support screening beginning at age 45 for average-risk adults, expanding the potential procedure base.[3] Surveillance colonoscopies and diagnostic procedures add volume, but utilization fluctuates with staffing, reimbursement and healthcare-system capacity.

The principal market segments are:

Segment	Commercial implication
Gastroenterology practices	Prescribing decisions are influenced by tolerability, patient adherence and samples
Hospital outpatient departments	Formularies and contracting exert stronger price pressure
Ambulatory surgery centers	Low preparation volume and operational convenience can support use
Retail pharmacy	Product availability and payer coverage affect prescription fulfillment
Medicare and commercial insurance	Tier placement and copay requirements can shift patients toward lower-cost products

The combination has a clinically meaningful convenience advantage over high-volume polyethylene glycol preparations. That advantage does not eliminate competition from other low-volume products, including sodium sulfate, potassium sulfate and magnesium sulfate solutions, oral sulfate solutions, and tablet-based bowel preparations.

What products compete with Clenpiq and Prepopik?

The principal competitive products include:

Product	Active ingredients or format	Competitive strength
Clenpiq	Sodium picosulfate, magnesium oxide and citric acid solution	Ready-to-drink format and low prep volume
Prepopik	Sodium picosulfate, magnesium oxide and citric acid powder	Established clinical familiarity
Suprep	Sodium sulfate, potassium sulfate and magnesium sulfate	Strong physician awareness and low-volume positioning
Sutab	Oral sulfate tablets	Avoids drinking a large volume of solution, but requires many tablets and water
Plenvu	Polyethylene glycol-based low-volume solution	Lower-volume PEG alternative
GoLYTELY and related PEG products	Polyethylene glycol electrolyte solution	Lower cost, broad institutional use and long clinical history

Sutab is the most direct convenience competitor because it also targets patients seeking to avoid large volumes of liquid. Suprep competes more directly on low-volume liquid preparation and has substantial commercial recognition.

The sodium picosulfate combination has an adherence proposition, but the active ingredients are not difficult to manufacture and the clinical category has several substitutes. This limits long-term pricing power.

When does sodium picosulfate bowel-prep exclusivity end?

FDA regulatory exclusivity and patent protection are separate.

Prepopik was approved in 2012, and Clenpiq was approved in 2017. Any original new-drug exclusivity periods have expired. The commercial question is therefore patent status, formulation differentiation and the availability of approved generic versions.

Protection category	Relevance
New chemical entity exclusivity	No longer the primary protection mechanism
Three-year clinical-investigation exclusivity	Relevant only to qualifying later approvals and has expired for the original products
Orange Book patents	May delay or condition approval of ANDAs if listed and unexpired
Formulation patents	Can protect ready-to-drink concentration, excipients, stability or packaging
Method-of-use patents	May cover colon-cleansing use, dosing schedules or administration protocols
Trade dress and trademarks	Protect product identity but do not block generic approval
Manufacturing know-how	Can create supply advantages without preventing regulatory approval of a competing product

FDA Orange Book listings must be assessed separately for each NDA and dosage form. Prepopik and Clenpiq are not interchangeable from a regulatory perspective merely because they contain the same active ingredients. Their formulations, concentrations, packaging and administration instructions can differ.[4]

What patents protect Clenpiq and Prepopik?

The most commercially relevant intellectual-property areas are formulation and dosage-form claims rather than broad composition claims.

Formulation patents

Potentially relevant formulation protection can cover:

• The concentration of sodium picosulfate, magnesium oxide and citric acid
• The aqueous ready-to-drink formulation used in Clenpiq
• Flavoring, pH control and stability systems
• Sachet composition and reconstitution characteristics for Prepopik
• Packaging that maintains stability or separates reactive components
• Specific dosing volumes and split-dose administration

A generic applicant can challenge listed patents through a Paragraph IV certification or may seek approval after patent expiry through a Paragraph III certification. The existence of a patent does not necessarily prevent a design-around formulation.

Method-of-use patents

Method claims may address bowel cleansing before colonoscopy, split dosing, administration timing or specific patient populations. Their commercial value is narrower than formulation claims because a generic applicant may attempt a skinny-label strategy that omits patented indications or instructions, subject to FDA labeling and induced-infringement risk.

Manufacturing and supply-chain protection

The active ingredients are established pharmaceutical materials. Manufacturing barriers are therefore moderate rather than fundamental. The more relevant operational risks are:

• Sourcing pharmaceutical-grade sodium picosulfate
• Controlling magnesium and citrate reaction behavior
• Achieving consistent taste and stability
• Meeting dissolution and content-uniformity specifications
• Maintaining packaging integrity
• Demonstrating bioequivalence or pharmaceutical equivalence where required

Ready-to-drink Clenpiq may present greater formulation and packaging complexity than a powder sachet, but neither format has the manufacturing difficulty associated with a biologic or complex injectable.

Are there Paragraph IV challenges to sodium picosulfate bowel preparations?

Paragraph IV risk is product-specific and depends on current Orange Book listings and ANDA activity. The key risk period occurs when an ANDA applicant certifies that a listed patent is invalid, unenforceable or not infringed.

A successful Paragraph IV filing can produce:

1. A patent-holder lawsuit within the statutory 45-day period.
2. A 30-month stay of ANDA approval in qualifying circumstances.
3. Settlement negotiations involving a licensed entry date.
4. Earlier generic entry if the patent challenge succeeds or the patent is not enforceable.
5. A limited commercial launch under a skinny label if method-of-use claims can be avoided.

For this product class, generic entry risk is higher than for products protected by a single complex-device patent because the active ingredients are known and multiple formulations are commercially feasible. Patent strength depends on claim scope, written-description support, prosecution history and the ability of a generic applicant to use a different concentration, excipient system or dosing presentation.

No biosimilar pathway applies. Any competitive challenge would proceed through the ANDA pathway for a small-molecule drug, not through the abbreviated pathway for biologics.

What is the Orange Book status of Clenpiq?

The Orange Book is the controlling public source for listed patents, exclusivity and therapeutic-equivalence information. Clenpiq is listed as an approved prescription bowel-preparation product under its NDA, while generic availability depends on approved ANDAs and their therapeutic-equivalence codes.

The practical Orange Book analysis should examine:

• The current Clenpiq NDA listing
• Any unexpired patents identified by the NDA holder
• Patent use codes
• First-applicant or 180-day exclusivity information
• Approved ANDAs and their “A,” “B” or other therapeutic-equivalence designations
• Whether the generic product is rated therapeutically equivalent to the referenced product

The regulatory status can change when FDA updates patent listings, approves an ANDA or removes an expired patent. FDA’s Drugs@FDA and Orange Book databases should be treated as the controlling records rather than commercial product databases.[4][5]

Which companies challenge or compete with this product?

The competitive field includes branded and generic manufacturers.

Ferring developed the product platform and held the original U.S. approvals. Bausch Health became associated with U.S. commercialization through its gastroenterology portfolio and the Salix business. Generic manufacturers can compete through ANDA approvals without duplicating the sponsor’s full clinical-development program.

Key competitive groups include:

• Bausch Health and Salix, through branded gastrointestinal commercialization
• Ferring Pharmaceuticals, as the original developer
• Generic drug manufacturers pursuing oral-solution or powder formulations
• Organon, through competing bowel-preparation products such as Sutab
• Sebela Pharmaceuticals, through competing bowel-preparation products such as Plenvu
• Brands and private-label suppliers serving hospitals, surgery centers and retail pharmacies

The commercial contest is based on formulary placement, prescription volume, adherence, sampling, payer rebates and supply reliability. Ingredient differentiation is limited.

What is the financial trajectory for sodium picosulfate, magnesium oxide and anhydrous citric acid?

The financial trajectory is best characterized as mature branded-product decline with residual value in formulation differentiation and channel management.

Revenue drivers

Positive drivers include:

• Growth in colonoscopy screening among adults aged 45 and older
• Preference for low-volume preparations
• Physician concern about patient completion of bowel preparation
• Use in ambulatory surgery centers
• Strong pharmacy availability
• Favorable insurance tier placement

Negative drivers include:

• Generic substitution
• Contracting pressure from hospitals and surgery centers
• Competition from Sutab, Suprep and Plenvu
• Limited ingredient differentiation
• Product shortages or pharmacy back orders
• Patient out-of-pocket costs
• Clinical restrictions for patients with renal, cardiac or electrolyte-related risks

Bausch Health does not publicly report a standalone revenue line for Clenpiq or Prepopik in its principal financial disclosures. That prevents a reliable product-level revenue estimate from public company filings. The relevant financial exposure is embedded within the company’s gastrointestinal and Salix portfolio reporting.[6]

Scenario analysis

Scenario	Market outcome	Financial effect
Branded maintenance	Stable colonoscopy volumes and limited generic substitution	Gradual revenue erosion with continued specialty-pharmacy and physician-channel value
Generic acceleration	Approved ANDAs gain broad payer preference	Rapid price compression and lower branded prescription volume
Convenience premium	Patients and physicians favor ready-to-drink low-volume preparations	Better retention for Clenpiq, but not necessarily higher category pricing
Competitive displacement	Sutab, Suprep or Plenvu captures formulary share	Lower utilization and reduced promotional return
Supply disruption	Manufacturing or distribution interruption	Temporary share loss and potential pharmacy substitution

The highest-probability long-term path is a declining branded revenue curve offset by continued demand for the underlying bowel-preparation category. The active ingredient combination can retain value if the sponsor preserves payer access, reliable supply and a meaningful convenience advantage.

What patent litigation or settlements affect the product?

Patent litigation risk is concentrated around ANDA launches. A lawsuit involving a listed formulation patent can delay approval, but the commercial outcome depends on the asserted claims and any settlement entry date.

Settlement terms in pharmaceutical cases may include:

• A licensed generic launch date before patent expiry
• No-early-entry provisions
• Authorized-generic arrangements
• Supply or distribution rights
• Payment or commercial consideration
• Agreements concerning future formulations

No litigation conclusion should be inferred solely from an Orange Book listing. A listed patent can expire, be delisted, be narrowed in litigation or remain enforceable only against a particular formulation. Court dockets and FDA records are required to distinguish active litigation from historical patent disputes.

How strong is the patent estate for this bowel-prep combination?

The patent estate is moderate to weak relative to products with composition-of-matter protection or complex delivery technology.

Factor	Assessment
Active ingredient novelty	Low; the ingredients are established
Formulation differentiation	Moderate, particularly for ready-to-drink products
Manufacturing complexity	Low to moderate
Generic design-around potential	Material
Clinical switching barriers	Limited
Brand recognition	Moderate
Payer leverage	High
Biosimilar protection	Not applicable

The strongest defensible position is likely the specific Clenpiq formulation, packaging and labeling combination. Broad protection for the active ingredients alone would provide limited exclusivity because sodium picosulfate, magnesium oxide and citric acid are individually established substances.

Key Takeaways

• Sodium picosulfate, magnesium oxide and anhydrous citric acid is a mature prescription bowel-preparation combination sold in U.S. formulations including Prepopik and Clenpiq.
• Clenpiq’s principal differentiation is a ready-to-drink, low-volume liquid format.
• The commercial market is driven by colonoscopy volumes, payer access, adherence and formulary placement.
• Generic entry risk is material because the active ingredients are established and formulation design-arounds are possible.
• Patent value is concentrated in formulation, packaging and method-of-use claims rather than composition-of-matter protection.
• No biosimilar risk applies because the product is a small-molecule drug.
• Public financial disclosures do not provide standalone Clenpiq or Prepopik revenue.
• Long-term branded revenue is more likely to decline than expand unless the product secures durable payer preference or a meaningful convenience premium.

Frequently Asked Questions

Is sodium picosulfate, magnesium oxide and citric acid the same as Suprep?

No. Suprep contains sodium sulfate, potassium sulfate and magnesium sulfate. The sodium picosulfate combination uses a stimulant laxative plus magnesium oxide and citric acid.

Can Clenpiq be substituted automatically for Prepopik?

Not necessarily. The products contain related active ingredients but use different dosage forms, concentrations and administration instructions. Substitution depends on FDA therapeutic-equivalence ratings, state pharmacy law and payer policy.

Is Clenpiq safe for patients with kidney disease?

The labeling warns about fluid and electrolyte abnormalities and requires clinical consideration in patients with renal impairment or other conditions affecting fluid balance.[2] It is not a product suitable for unrestricted use across all renal-risk patients.

Does the product require a prescription?

U.S. Prepopik and Clenpiq products were approved as prescription bowel preparations. Regulatory status outside the United States can differ by jurisdiction and formulation.

What is the main investment risk for the product?

The main risk is erosion of branded volume and net price from generic substitution and competing low-volume preparations. The category itself has durable procedure-linked demand, but the individual branded product has limited protection from ingredient-level competition.

References

1. U.S. Food and Drug Administration. (2012). Prepopik prescribing information. Drugs@FDA.
2. U.S. Food and Drug Administration. (2017). Clenpiq prescribing information. Drugs@FDA.
3. U.S. Preventive Services Task Force. (2021). Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. JAMA, 325(19), 1965-1977.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
6. Bausch Health Companies Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.